OpenAlex
PricingAboutJobs
Log inGet started
Work

Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?

HTML

Year: 2020
Type: review
Source: Expert Opinion on Investigational Drugs
DOI: 10.1080/13543784.2020.1718104
Authors: Michael Ritchie, Ibrahim A. Hanouneh, Mazen Noureddin, Timothy Rolph, Naim Alkhouri
Institutions: Abbott Northwestern Hospital, MNGI Digestive Health, Mayo Clinic, Cedars-Sinai Medical Center, The University of Texas at San Antonio Health Science Center, Texas Liver Institute
Language: English

Topic: Fibroblast Growth Factor Research
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: FGF21, non-alcoholic fatty liver disease, β-Klotho, FGF receptor signaling, hepatic steatosis, liver fibrosis, glucose metabolism, fat metabolism, drug safety, bone homeostasis, injection site reactions
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2999131584
FWCI: 0.628
Cites: 42
Cited by: 42
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security